Wainua Stumbles in Phase III ATTR-CM Trial, Missing Primary Endpoint for AstraZeneca

summarizeSummary

Wainua, from AstraZeneca and Ionis, failed its Phase III CARDIO-TTRansform trial in ATTR-CM, missing the primary endpoint of reducing cardiovascular death and events. The drug showed no benefit when added to standard-of-care stabilisers, though a monotherapy subgroup showed nominal significance. This marks a major pipeline disappointment for a key growth indication.

check_boxKey Events · Product Development and Regulatory · AZN

• Phase III ATTR-CM Trial Misses Primary Endpoint

  In the CARDIO-TTRansform trial, Wainua (eplontersen) failed to meet the primary composite endpoint of cardiovascular mortality and recurrent CV clinical events at 140 weeks versus placebo, across 1,432 ATTR-CM patients.

• No Benefit on Top of Standard-of-Care Stabilisers

  At baseline, 57% of patients in each arm were on a TTR stabiliser; adding Wainua showed no treatment effect in this subgroup. A prespecified monotherapy subgroup did show nominally significant benefit, but the overall trial failed.

• Major Pipeline Setback for Key Growth Indication

  With 300,000–500,000 patients worldwide, ATTR-CM represents a large market opportunity. This failure removes a significant near-term revenue catalyst and raises doubts about the drug's broader utility in cardiomyopathy.

• Full Data Presentation at ESC Congress August 2026

  The complete dataset will be presented by AstraZeneca and Ionis at the European Society of Cardiology Congress in August 2026, a crucial event for determining any potential path forward, including in monotherapy.

auto_awesomeAnalysis · AZN · Life Sciences

A significant setback emerges from the CARDIO-TTRansform trial, where Wainua (eplontersen) failed to meet its primary endpoint of reducing cardiovascular mortality and recurrent CV events in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The drug had been expected to unlock a large cardiomyopathy market, estimated at 300,000–500,000 patients worldwide. This failure removes a major near-term growth catalyst and casts doubt on the broader ATTR franchise strategy, particularly since Wainua showed no benefit when added to existing stabiliser therapy—the current standard of care. While a nominal benefit in monotherapy patients offers a glimmer of hope, it is insufficient to salvage the trial. Full data at ESC in August 2026 will be critical for assessing any path forward.